Dermatology OTC Switches Loom Next For Consumer Health Growth
This article was originally published in The Pink Sheet
Dermatology OTC switch products for acne, eczema and psoriasis are likely to emerge, says Kline analyst Laura Mahecha. Switches, the return of recalled OTC brands and market consolidation drove a 4.2% increase for the US consumer health market in 2015.
You may also be interested in...
J&J Invests In Consumer Business For Long Haul, Not Quick Sale
"We believe the consumer business at J&J is an absolute integral part of our company," says CEO Alex Gorsky.
Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval
Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.
Sanofi 'Fine-Tuning' Cialis OTC Switch Application
Potential Cialis switch and the pending addition of Boehringer Ingelheim's consumer business are the revenue drivers highlighted by company execs on earnings call; second-quarter consumer health product revenues slipped 4.3% to $886.4m as a mild allergy season in the US and economic chaos in Venezuela drag down sales.